# Evaluation of Safety and Efficacy of PDP-716

> **NCT03450629** · PHASE3 · COMPLETED · sponsor: **Sun Pharma Advanced Research Company Limited** · enrollment: 682 (actual)

## Conditions studied

- Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Brimonidine Tartrate Ophthalmic Suspension
- **DRUG:** Brimonidine Tartrate Ophthalmic Solution

## Key facts

- **NCT ID:** NCT03450629
- **Lead sponsor:** Sun Pharma Advanced Research Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-13
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 682 (ACTUAL)
- **Last updated:** 2022-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03450629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03450629, "Evaluation of Safety and Efficacy of PDP-716". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03450629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*